Table 1.
Clinical data summary for SMC and TCGA
| SMC | TCGA | Statistical significance | |
|---|---|---|---|
| Subjects (n) | 187 | 1,116 | |
| Patient age (yr) | 39.3 ± 8.5 | 58.3 ± 13.2 | p < 2.2e-16 |
| Tumor purity (%) | 71 ± 17.8 | 77.7 ± 10.7 | p = 0.0005 |
| Menopausal status (n(%)) | |||
| Pre-menopausal | 165 (88.2%) | 232 (20.8%) | p = 1.12e-76 |
| Post-menopausal | 19 (10.2%) | 715 (64.1%) | p = 2.4e-68 |
| Peri-menopausal | 41 (3.7%) | ||
| N/A | 128 (11.5%) | ||
| Clinical subtype (n(%)) | |||
| ER+ | 103 (55.1%) | 480 (43.0%) | p = 0.04 |
| ER+/HER2+ | 27 (14.4%) | 116 (10.4%) | |
| HER2+ | 15 (8%) | 32 (2.9%) | p = 0.07 |
| TNBC | 37 (19.8%) | 121 (10.8%) | |
| N/A | 5 (2.7%) | 367 (32.9%) | |
| TNM stage (n(%)) | |||
| I | 27 (14.4%) | 177 (15.9%) | |
| II | 101 (54%) | 605 (54.2%) | |
| III | 58 (31%) | 237 (21.2%) | |
| V | 1 (0.5%) | 18 (1.6%) | |
| N/A | 79 (7.1%) | ||
| Histology subtype (n(%)) | |||
| Lobular carcinoma | 7 (3.7%) | 193 (17.3%) | p = 2.9e-08 |
| Ductal Carcinoma | 172 (92.0%) | 830 (74.4%) | p = 2.9e-08 |
| Others | 8 (4.3%) | 37 (3.3%) | |
| N/A | 56 (5.0%) | ||
| Race (n(%)) | |||
| Asian | 187 (100%) | 57 (5.1%) | p = 2.53e-193 |
| Black | 158 (14.2%) | ||
| White | 745 (66.8%) | ||
| N/A | 156 (14%) |
For SMC vs. TCGA comparisons of continuous and categorical variables, p values were calculated using Student’s t test and Fisher’s exact test respectively